Transfemoral TAVR implantation: are we arriving too late?
Results from the first randomized trial assessing transfemoral TAVR in patients with moderate aortic stenosis and ventricular dysfunction.
Results from the first randomized trial assessing transfemoral TAVR in patients with moderate aortic stenosis and ventricular dysfunction.
This retrospective study analyzed more than three thousand patients who underwent surgical mitral valve repair for degenerative mitral regurgitation, with a 10-year follow-up.
This study aimed to identify the risk factors associated with permanent pacemaker (PPM) implantation following tricuspid valve (TV) surgery.
This retrospective study investigated the prognostic implications of tricuspid regurgitation (TR) in a cohort of 2679 patients who underwent surgical aortic valve replacement (AVR), specifically assessing the potential benefit of concomitant tricuspid valve intervention in those with moderate TR.
This observational study explores the association between mitral regurgitation (MR) severity and both cardiovascular and all-cause mortality.
A meta-analysis of four randomized controlled trials (RCTs) comparing early aortic valve replacement (either surgical or transcatheter) with a conservative strategy of close clinical surveillance in patients with asymptomatic severe aortic stenosis.
This multicenter observational study evaluates the impact of percutaneous edge-to-edge tricuspid valve repair on overall survival in patients with tricuspid regurgitation across different disease stages.
Meta-analysis of the longest available follow-up outcomes from the six main randomized trials comparing TAVI and SAVR in low surgical risk patients in terms of survival and stroke.
The Cardiac Surgery team at the Cleveland Clinic (Cleveland, Ohio, USA) reviewed multivalve reoperations (involving more than one valve) performed from 2008 to 2022 and identified the determinants of operative mortality in these procedures.
A retrospective observational study evaluating patients who underwent TAVI to identify predictive factors for atrioventricular block (AVB) within 24 hours to 30 days post procedure and to develop a risk stratification tool.